Cell shape change precedes staurosporine-induced stabilization and accumulation of p27kip1

Experimental Cell Research

Volumn 280, Issue 2, 2002, Pages 233-243

  Nishi, Kayoko ^a   Schnier, Joachim B ^a   Bradbury, Morton E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOCHALASIN D; DIACETYL OXIME; PROTEIN; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE G1 PHASE; CELL SHAPE; CELL VIABILITY; CONTROLLED STUDY; CYTOSKELETON; FIBROBLAST; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY;

EID: 0036430684     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1006/excr.2002.5637     Document Type: Article

References (41)

1. Arai, N., Shiomi, K., Takamatsu, S., Komiyama, K., Shinose, M., Takahashi, Y., Tanaka, Y., Iwai, Y., Liu, J. R., and Omura, S. (1997). Amphistin, a new melanogenesis inhibitor, produced by an actinomycete. J. Antibiot. (Tokyo) 50, 808-814.
2. Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., and Tomita, F. (1986). Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem. Biophys. Res. Commum. 135, 397-402.
3. Ward, N. E., and O'Brian, C. A. (1992). Kinetic analysis of protein kinase C inhibition by staurosporine: Evidence that inhibition entails inhibitor binding at a conserved region of the catalytic domain but not competition with substrates. Mol. Pharmacol. 41, 387-392.
4. Nakano, H., Kobayashi, E., Takahashi, I., Tamaoki, T., Kuzuu, Y., and Iba, H. (1987). Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J. Antibiot. (Tokyo) 40, 706-708.
5. 3H]-staurosporine on various protein kinases. Biochem. Biophys. Res. Commun. 171, 189-195.
6. Gadbois, D. M., Hamaguchi, J. R., Swank, R. A., and Bradbury, E. M. (1992). Staurosporine is a potent inhibitor of p34cdc2 and p34cdc2-like kinases. Biochem. Biophys. Res. Commun. 184, 80-85.
7. Crissman, H. A., Gadbois, D. M., Tobey, R. A., and Bradbury, E. M. (1991). Transformed mammalian cells are deficient in kinase-mediated control of progression through the G1 phase of the cell cycle. Proc. Natl. Acad. Sci. USA 88, 7580-7584.
8. Abe, K., Yoshida, M., Usui, T., Horinouchi, S., and Beppu, T. (1991). Highly synchronous culture of fibroblasts from G2 block caused by staurosporine, apotent inhibitor of protein kinases. Exp. Cell Res. 192, 122-127.
9. Lin, Y., Chrest, F. J., and Gabrielson, E. W. (1992). Reversible G1 arrest of a human lung epithelial cell line by staurosporine. J. Cell Physiol. 152, 646-653.
10. Schnier, J. B., Gadbois, D. M., Nishi, K., and Bradbury, E. M. (1994). The kinase inhibitor staurosporine induces G1 arrest at two points: Effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res. 54, 5959-5963.
11. Schnier, J. B., Nishi, K., Goodrich, D. W., and Bradbury, E. M. (1996). G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc. Natl. Acad. Sci. USA 93, 5941-5946.
12. Nishi, K., Schnier, J. B., and Bradbury, E. M. (1998). The accumulation of cyclin-dependent kinase inhibitor p27kip1 is a primary response to staurosporine and independent of G1 cell cycle arrest. Exp. Cell Res. 243, 222-231.
13. Hedberg, K. K., Birrell, G. B., Habliston, D. L., and Griffith, O. H. (1990) Staurosporine induces dissolution of microfilament bundles by a protein kinase C-independent pathway. Exp. Cell Res. 188, 199-208.
14. Mobley, P. L., Hedberg, K., Bonin, L., Chen, B., and Griffith, O. H. (1994). Decreased phosphorylation of four 20-kDa proteins precedes staurosporine-induced disruption of the actin/myosin cytoskeleton in rat astrocytes. Exp. Cell Res. 214, 55-66.
15. Yang, R., Fu, W., Wang, S., Liu, T., and Lin-Shiau, S. (1997). Mechanism of the morphological changes induced by staurosporine in rat osteoblasts. Calcif. Tissue Int. 61, 68-73.
16. Schliwa, M., Nakamura, T., Porter, K. R., and Euteneuer, U. (1984). A tumor promoter induces rapid and coordinated reorganization of actin and vinculin in cultured cells. J. Cell Biol. 99, 1045-1059.
17. Sobue, K., Fujio, Y., and Kanda, K. (1988). Tumor promoter induces reorganization of actin filaments and calspectin (fodrin or nonerythroid spectrin) in 3T3 cells. Proc. Natl. Acad. Sci. USA 85, 482-486.
18. Takasuka, T., Ishibashi, S., and Ide, T. (1987). GC-7 cells are growth arrested by cytochalasin D at two different points in the cell cycle. Exp. Cell Res. 173, 287-293.
19. Sympson, C. J., and Geoghegan, T. E. (1990). Actin gene expression in murine erythroleukemia cells treated with cytochalasin D. Exp. Cell Res. 189, 28-32.
20. Huang, S., Chen, C. S., and Ingber, D. E. (1998). Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. Mol. Biol. Cell 9, 3179-3193.
21. Reshetnikova, G., Barkan, R., Popov, B., Nikolsky, N., and Chang, L. S. (2000). Disruption of the actin cytoskeleton leads to inhibition of mitogen-induced cyclin E expression, Cdk2 phosphorylation, and nuclear accumulation of the retinoblastoma protein-related p107 protein. Exp. Cell Res. 259, 35-53.
22. Fang, F., Orend, G., Watanabe, N., Hunter, T., and Ruoslahti, E. (1996). Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271, 499-502.
23. Zhu, X., Ohtsubo, M., Bohmer, R. M., Roberts, J. M., and As-soian, R. K. (1996). Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. J. Cell Biol. 133, 391-403.
24. Schulze, A., Zerfass-Thome, K., Berges, J., Middendorp, S., Jansen-Durr, P., and Henglein, B. (1996). Anchorage-dependent transcription of the cyclin A gene. Mol. Cell Biol. 16, 4632-4638.
25. Koff, A., and Polyak, K. (1995). p27KIP1, an inhibitor of cyclin-dependent kinases. Prog. Cell Cycle Res. 1, 141-147.
26. Slingerland, J., and Pagano, M. (2000). Regulation of the cdk inhibitor p27 and its deregulation in cancer. J. Cell Physiol. 183, 10-17.
27. Pagano, M. (1997). Cell cycle regulation by the ubiquitin pathway. FASEB J. 11, 1067-1075.
28. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F., and Rolfe, M. (1995). Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-685.
29. Shirane, M., Harumiya, Y., Ishida, N., Hirai, A., Miyamoto, C., Hatakeyama, S., Nakayama, K., and Kitagawa, M. (1999). Down-regulation of p27(Kip1) by two mechanisms, ubiquitin-mediated degradation andproteolytic processing. J. Biol. Chem. 274, 13886-13893.
30. Vlach, J., Hennecke, S., and Amati, B. (1997). Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J. 16, 5334-5344.
31. Alessandrini, A., Chiaur, D. S., and Pagano, M. (1997) Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 11, 342-345.
32. Sheaff, R. J., Groudine, M., Gordon, M., Roberts, J. M., and Clurman, B. E. (1997). Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev. 11, 1464-1478.
33. Frost, V., Al-Mehairi, S., and Sinclair, A. J. (2001). Exploitation of a non-apoptotic caspase to regulate the abundance of the cdkI p27(KIP1) in transformed lymphoid cells. Oncogene 20, 2737-2748.
34. Malek, N. P., Sundberg, H., McGrew, S., Nakayama, K., Kyriakides, T. R., Roberts, J. M., and Kyriakidis, T. R. (2001). A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 phase. Nature 413, 323-327.
35. Flanagan, M. D., and Lin, S. (1980). Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J. Biol. Chem. 255, 835-838.
36. Urbanik, E., and Ware, B. R. (1989). Actin filament capping and cleaving activity of cytochalasins B, D, E, and H. Arch. Biochem. Biophys. 269, 181-187.
37. Chrzanowska-Wodnicka, M., and Burridge, K. (1996). Rho-stimulated contractility drives the formation of stress fibers and focal adhesions. J. Cell Biol. 133, 1403-1415.
38. Assoian, R. K., and Zhu, X. (1997). Cell anchorage and the cytoskeleton as partners in growth factor dependent cell cycle progression. Curr. Opin. Cell Biol. 9, 93-98.
39. Yamazaki, Y., Sanokawa, R., Fujita, Y., Zhou, D., Kawasaki, K., Tanaka, H., Komatsu, T., Nagasawa, T., and Oka, S. (1999). Cytoplasmic elongation and rupture in megakaryoblastic leukemia cells via activation of adhesion and motility by staurosporine on fibronectin-bound substratum. J. Cell Physiol. 179, 179-192.
40. Koyama, H., Raines, E. W., Bornfeldt, K. E., Roberts, J. M., and Ross, R. (1996). Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 87, 1069-1078.
41. Hirai, A., Nakamura, S., Noguchi, Y., Yasuda, T., Kitagawa, M., Tatsuno, I., Oeda, T., Tahara, K., Terano, T., Narumiya, S., Kohn, L. D., and Saito, Y. (1997). Geranyl-geranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progressionfrom G1 to S phase in growth-stimulated rat FRTL-5 cells. J. Biol. Chem. 272, 13-16.